Inclusion Criteria:
* Arm 1:
Subjects will be considered qualified for enrollment if they meet the following criteria:
Subjects and/or Legally Authorized Representative (LAR) must voluntarily provide written Informed Consent, consisting of reading, signing, and dating the Informed Consent document after the Principal Investigator, sub-Principal Investigator, or other designated Study Staff member has explained the Study procedures, risks, and contact information.
Able and willing to comply with all Study requirements.
Subject can be Male or Female but must be over 21 years of age.
Subject is currently under the care of a Primary Care Physician.
Subject has an anticipated survival of greater than two months.
Subject has a moderate to high exudate wound that has visible fluorescence when using MolecuLightDX™ or MolecuLight i:X™ imaging.
Arm 2:
Subjects will be considered qualified for enrollment if they meet the following criteria:
Subjects and/or Legally Authorized Representative (LAR) must voluntarily provide written Informed Consent, consisting of reading, signing, and dating the Informed Consent document after the Principal Investigator, sub-Investigator, or other designated Study Staff member has explained the Study procedures, risks, and contact information.
Able and willing to comply with all Study requirements.
Subject can be Male or Female but must be over 21 years of age.
Subject is currently under the care of a Primary Care Physician.
Subject has an anticipated survival of greater than two months.
Subject has a moderate to high exudate wound.
\*For this Study, moderate exudate is defined as a wound that may require a dressing change 2-3 times a week based on provider judgement. Heavy exudate is defined as a wound that may require a dressing change 4 or more times a week based on provider judgement.
Exclusion Criteria:
* Subject's target treatment area has a surface area larger than 5 cm2.
Known sensitivity or allergy to the Study Device or adhesives/adhesive-related products.
Current use of topical ointments, including over-the-counter products and prescription drugs, on or near the intended treatment area.
Current use or recent history (within the past 14 days) of antibiotics, either oral, systemic, or topical.
Undergoing therapy with another investigational agent that may affect the WoundCueTM Kit's performance within thirty (30) days of Study Visit 1 or planned participation overlapping with this Study.
Women who are pregnant, breastfeeding, or intend to become pregnant during the course of the Study.
Medical condition that, in the opinion of the Principal Investigator, would preclude safe Subject participation in the Study.
Adults who, in the judgment of the Investigator, lack the capacity to provide informed consent for themselves
